# Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

> **NCT07079423** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 35 (estimated)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** Teclistamab (Tec)

## Key facts

- **NCT ID:** NCT07079423
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-28
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07079423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07079423, "Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07079423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*